An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain ...

These abstracts summarize Versamune ® HPV (PDS0101) studies to be presented during the Head and Neck Cancer Poster Session taking place May 30-June 3, 2025, in Chicago, Illinois. Kirk Shepard, M.D., ...

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary ...

Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodiesLong-term outcomes and survival data for Ziihera® (zanidatamab-hrii), ...

Finance Income, net was $1.0 million for the three months ended March 31, 2025, compared to $0.7 million in the same period ...

Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an ...

Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025 NT219 data presented at ...

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20%. Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advan ...

Kura Oncology, Inc. (Nasdaq: KURA, "Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin”) today announced that an a ...

GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion ...

Alicia Alford, a recent graduate of the BULLS Life Sciences Academy and Durham Technical Community College, said Accelerate NC had helped her get her new “big girl job” as a Manufacturing Associate I ...